DBXO-1 / Deck Bio - LARVOL DELTA

Preclinical characterization of DBXO-1, a multi-pMHC targeted bispecific T cell engager for major solid tumors (AACR 2026) - "Finally, DBXO-1 mediated potent, dose-dependent cytotoxicity on multiple HLA-A*02:01+ cell lines expressing the target signature, while no activity was observed in absence of either target expression or HLA restriction.Taken together, these data support continued preclinical development of DBXO-1, with the goal of entering a first-in-human clinical trial in 2027. Initial clinical development is anticipated in biomarker-selected patient populations across major solid tumors, including non-small cell lung, head and neck, and gastroesophageal cancers."

Bispecific • First-in-human • IO biomarker • Preclinical • Gastroesophageal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HLA-A

Deck Bio Launches Multi-Target T Cell Engager Platform for Solid Tumors, With Preclinical Data to be Presented at AACR 2026 (PRNewswire) - "The company's lead program, DBXO-1, is a multi-target T cell engager being developed for solid tumor indications, including non-small cell lung cancer and gastroesophageal cancer. Additional details will be highlighted during the upcoming presentation at the AACR Annual Meeting 2026."

Preclinical • Solid Tumor

Deck Bio Presents Preclinical Data on DBXO-1, a Multi-pMHC Targeted T Cell Engager, at AACR 2026 (PRNewswire) - "The data highlight Deck Bio's strategy to overcome key limitations of T cell engagers in solid tumors, including low antigen density, tumor heterogeneity, and the scarcity of tumor-specific surface targets....DBXO-1 enables precise targeting of intracellular cancer antigens in a novel T cell engager format (dbTCE)."

Preclinical • Solid Tumor